Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio

Technavio has released a new market research report on the global PD-1 and PD-L1 inhibitors market for the period 2019-2023. (Graphic: Business Wire)

LONDON--()--The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to the latest market research report by Technavio.

Globally, the prevalence of cancer has seen a significant rise in recent years, and the global oncology therapeutics market has witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a substantial unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors. With an increase in cases of cancer, various companies are researching on developing novel PD-1 and PD-L1 inhibitors to capture the vast unmet need, and the market has witnessed the approval of these drugs in recent years. The increasing approvals of these inhibitors for the treatment of various cancer indications are expected to capture the huge unmet need, which is expected to add significant value to the global PD-1 and PD-L1 inhibitors market during the forecast period.

As per Technavio, the strong pipeline will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global PD-1 and PD-L1 Inhibitors market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Global PD-1 and PD-L1 Inhibitors market: Strong Pipeline

The global PD-1 and PD-L1 inhibitors market witnesses the presence of various large pharmaceutical players with novel therapies in the pipeline for the treatment of various types of cancer. The superior efficacy of approved PD-1 and PD-L1 inhibitors has led to various companies stepping forward to research more advanced therapies to treat multiple cancer indications. As a result, the pipeline of these inhibitors is increasing, with highly promising therapies in the late stages of clinical trials. The approved treatments such as OPDIVO, KEYTRUDA, and IMFINZI are also being studied in clinical trials for multiple cancer indications, owing to their high efficacy in blocking PD-1 and PD-L1 signaling pathway for cancer cells. Thus, with such benefits, the market is expected to showcase a positive outlook during the forecast period.

“Apart from the strong pipeline, the proven efficacy of PD-1 and PD-L1 inhibitors, reimbursement programs, and special drug designations are some major aspects that are expected to contribute largely to the growth of the global PD-1 and PD-L1 Inhibitors market, during the forecast period,” says a senior analyst at Technavio.

Global PD-1 and PD-L1 Inhibitors market: Segmentation analysis

This market research report segments the global PD-1 and PD-L1 Inhibitors market by application (solid tumors, blood-related tumors) and geographical regions (North America, Europe, Asia, ROW).

The North American region led the market in 2018 with a market share close to 52%, followed by Europe, Asia, and ROW respectively. However, during the forecast period, the European region is expected to register the highest incremental growth, followed by ROW.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com